key: cord-0908677-zsm7v3am
authors: Kang, Yue; Xu, Silu
title: Comprehensive overview of COVID‐19 based on current evidence
date: 2020-05-22
journal: Dermatol Ther
DOI: 10.1111/dth.13525
sha: 563e5974e17c0e58b66a7c65b577cb00dd8673fd
doc_id: 908677
cord_uid: zsm7v3am

In December 2019, twenty‐seven pneumonia patients with unknown causes originated in South China seafood market in Wuhan. The virus infection spread rapidly and swept through China in less than a month. Subsequently, the virus was proven a novel coronavirus and named SARS‐CoV‐2. The outbreak of novel coronavirus has been determined as a Public Health Emergency of International Concern (PHEIC) by WHO on January 31, 2020. Similar to other coronaviruses like the Middle East Respiratory Syndrome (MERS) CoV and Severe Acute Respiratory Syndrome (SARS) CoV, the novel coronavirus was reported to spread via respiratory droplets and close contact from human to human, which means the virus is highly infectious and dangerous. Unfortunately, till now the virus has spread to over 200 countries/territories/areas around the world and the Coronavirus Disease 2019 (COVID‐19) outbreak is continuing to grow. Currently, information sharing and transparency are essential for risk assessment and epidemic control in all endemic areas. In this article, we compared SARS‐CoV‐2 with SARS‐CoV and influenza virus, discussed current researching progress of COVID‐19, including clinical characteristics, pathological changes, treatment measures, and so on.

The novel coronavirus has caused many cases of viral pneumonia since According to the antigenicity of nucleoprotein and membrane matrix protein, influenza viruses are mainly divided into three types:

A, B, and C. The structure of influenza virus is just like a sphere with a diameter of 80 to 120 nm which consists of three parts: envelope, matrix protein and core. The genetic material in the core called ss-RNA is responsible for virus replication. Matrix proteins are closely bound to the outer envelope to protect the core of the virus and maintain the spatial structure. In fact, there is small amount of membrane proteins (M2) besides matrix protein (M1) in the skeleton. M2 protein has the function of ion channel (mainly Na + channel) and regulating pH value in membrane. The outer surface is mainly composed of phospholipid bilayer with two significant kinds of glycoprotein protrusions, hemagglutinin (HA) and neuraminidase (NA), 5 the former can assist the fusion of virus envelope and host cell membrane while the latter has the ability of hydrolyzing sialic acid to cut off the connection between them. 6, 7 Unlike the structure of influenza virus, coronavirus with a diameter of 60 to 220 nm has the largest genome among all RNA viruses which has been found currently, it can be divided into four genera, named α, β, γ, and δ, α-type includes porcine epidemic γ-type contains avian infectious bronchitis while the last one includes parrot coronavirus (PaCoV) and porcine delta-coronavirus (PDCoV). 8 There are three types of glycoproteins existed on the surface of the membrane: spike protein (S), envelope protein (E), and membrane protein (M), the spike protein will form large protrusions on the virus surface and lead to the crown-like appearance. It is worth mentioning that the E and M protein participate in virus assembly while the S protein mediates the entrance of host cells. 9 In terms of infective mode, influenza virus is dependent on clathrin-mediated endocytosis and sialic acids which are distributed on the host cells and are absolutely important in the entry progress.

HA proteins are used to bind to sialic acids and then genetic material penetrates into the target cell through the material transport channel, combines with the DNA and finally many progeny viruses are formed. 10-13 NA is responsible for catalyzing the hydrolysis of glycoside bond so that the mature virus particles eventually leave the host cells and infect new epithelial cells. [14] [15] [16] [17] [18] Compared with coronavirus, S protein exists in the form of homologous trimer and its monomer can be recognized by protease. It is a weapon to attack invading cells and it can be divided into S1 and S2 subunits.

Between them, the N-terminal S1 subunit consists of four β-rich domains which are mainly used for receptor recognition; S2 has a second digestion site, membrane fusion peptide and two heptad repeat domains, whose main function is to mediate the fusion of virus envelope and host cell membrane. 19 Sialic acids were also considerable in this progress and they produce a marked effect on the binding of S protein, after which virus penetrates into host cells in a neutral or low-PH environment, then the nucleocapsid, which encapsulates genetic material, is allowed to pass through and enter the cytoplasm to begin replication cycles. 20, 21 Similarly, it has been reported that all the coronaviruses rely on clathrin-mediated endocytosis to enter into target cells, the notable difference among various coronaviruses depends on whether the S protein is cleaved in early endosomes or lysosomes. ache and systemic pain. However, the coronavirus is much more infectious due to the huge damage to respiratory tract, not only can it cause fibrosis in the lungs, but also lead to spleen shrinking, myocardial cell necrosis, hepatobiliary congestion and brain edema. Chest tightness and dyspnea are common symptoms in patients infected coronavirus and severe patients developed rapidly into acute respiratory distress syndrome, septic shock, metabolic acidosis, and coagulation dysfunction. 2 The most terrible sequela is the impairment of pulmonary repair function caused by pulmonary fibrosis. 23, 24 At first, the source of SARS was locked in civet cats by experts. But according to more in-depth researches, bats were found to be the final producers of SARS-CoV. 23 It is alarming that there are many similarities between SARS-CoV-2 and SARS-CoV, such as propagation characteristics, epidemiology, and acting mechanism, and so on, 25 cating that the potential targets of SARS-CoV-2 may be located in the lower airway. 29 It has been generally accepted that the parameter scientists use to determine how easy the virus to spread is known as the "basic reproduction number," or R0, it has been reported that R0 of SARS-CoV-2 is around 2.68 with 2.47 to 2.86 of 95% credible interval, this means although its propagation characteristics are similar to SARS-CoV, the former is less contagious than the latter. 24, 30 At present, the mortality of COVID-19 in China is 4.1%, 3 lower than 9.6% of SARS reported by WHO. 31 

According to clinical data, the general incubation period of all the patients is almost 1 to 14 days, among which only one patient has incubation period of 24 days. 32 The clinical manifestations of the cases including fever, hard breathing, and lungs infiltrative lesions on chest radiograph. 33 It is hard to predict that a few asymptomatic infections are still contagious, this makes the investigation much more difficult. Based on the previous results, most of the patients, aged from 25 to 49 and about 30% were aged from 50 to 64. In fact, the SARS-CoV-2 is susceptible to all populations, but the elderly and patients with chronic diseases are more likely to suffer severe conditions after infection because the elderly are not as resistant as young people due to the degradation of various physiological functions. It is also worth mentioning that pregnant women and infants are also susceptible groups, mainly due to their low immunity. 34, 35 On February 5, 2020, a newborn infant that was delivered by his infected mother during the epidemic in Wuhan had been tested positive for SARS-CoV-2, this reminds us that the virus not only spread by respiratory droplets and close contact, but also by mother-to-child transmission. 35 Meanwhile, it is possible to propagate through aerosols when exposed to high concentration aerosols for a long time in a closed environment.

And because novel coronavirus can be isolated from feces and urine, attention should be paid to the spread of aerosols or contacts caused by environmental pollution by feces and urine. 36 There are currently no specific drugs for COVID-19, but the good news is that several medicines have been proven effective and are ready for clinical treatment. 36, 43 For example, some patients eased after taking oseltamivir. Lopinavir/Ritonavir which is used for Acquired Immune Deficiency Syndrome (AIDS) treatment, was very effective in slowing down the progress of disease. 44 Remdesivir is a drug developed by GILD for anti-Ebola virus infection. Vitro experiments showed that the drug had a good inhibition on the novel coronavirus and with a good safety profile, and it also achieved a successful treatment in one patient in the United States.

Remdesivir has been used on Phase III clinical treatment in Wuhan (NCT04252664). 45 Furthermore, nucleoside analogues, neuraminidase inhibitors, peptide (EK1), arbidol, chloroquine, RNA synthesis inhibitors (such as TDF and 3TC), specific monoclonal antibody of SARS-CoV (CR3022) were also found have anti-virus effect. Not long ago, Nanshan Zhong found that using the plasma of the cured patients to import into the severe patients is a useful strategy, 38 which had been applied to treating SARS since 2003.

In addition, in view of cytokine storm is an important node in COVID-19 patients transforming from mild to severe and critical illness, and is also a cause of death in severe and critical cases. became a pandemic. Although experimental study has made a breakthrough, there is still limited knowledge for the progress of SARS-CoV-2 researching, the development of effective drugs and vaccines are still in their infancy, so it is urgent to develop many more effective testing approaches, preventive measures, and treatment plans. Furthermore, we should wash hands frequently, maintain social distancing and practice respiratory hygiene. Secondly, if we have fever, cough and difficulty breathing, seek medical care early. 46 

The progress of 2019 novel coronavirus (2019-nCoV) event in China

Overview of the 2019 novel coronavirus (2019-nCoV): the pathogen of severe specific contagious pneumonia (SSCP)

National Health Commission of the People's Republic of China. National Health Commission's briefing on the pneumonia epidemic situation

WHO's Coronavirus disease 2019 (COVID-19) Situation Report-73

Human influenza a virus hemagglutinin glycan evolution follows a temporal pattern to a glycan limit

Glycan analysis and influenza A virus infection of primary swine respiratory epithelial cells: the importance of NeuAc{alpha}2-6 glycans

Host cellular signaling induced by influenza virus

Alterations in sialic-acid O-acetylation glycoforms during murine erythrocyte development

Structure, function, and evolution of coronavirus spike proteins

Entry of influenza A virus: host factors and antiviral targets

N-glycan structures of human alveoli provide insight into influenza A virus infection and pathogenesis

Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection

Quantitative glycome analysis of N-glycan patterns in bladder cancer vs normal bladder cells using an integrated strategy

Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase

A novel natural influenza A H1N1 virus neuraminidase inhibitory peptide derived from cod skin hydrolysates and its antiviral mechanism

Influenza neuraminidase. Influenza Other Respi Viruses

Glycan array analysis of influenza H1N1 binding and release

Structural basis for substrate specificity of mammalian neuraminidases

Mechanisms of coronavirus cell entry mediated by the viral spike protein

Feline coronavirus: insights into viral pathogenesis based on the spike protein structure and function

The avian coronavirus spike protein

Isolation and characterization of 2019-nCoVlike coronavirus from Malayan pangolins

Three emerging coronaviruses in two decades

Emerging threats from zoonotic coronavirusesfrom SARS and MERS to 2019-nCoV

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Severe acute respiratory syndrome

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The reproductive number of COVID-19 is higher compared to SARS coronavirus

A novel coronavirus emerging in China -key questions for impact assessment

Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China

Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak

2019-nCoV epidemic: what about pregnancies?

Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections

First case of 2019 novel coronavirus in the United States

Single-cell analysis of ACE2 expression in human kidneys and bladders reveals a potential route of 2019-nCoV infection

National Health Commission of the People's Republic of China and National Administration of Traditional Chinese Medicine. Diagnosis & Treatment Scheme for Novel Coronavirus Pneumonia (Trial)

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

The global spread of 2019-nCoV: a molecular evolutionary analysis. Pathog Glob Health

Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing

Pre-and Posttreatment chest CT findings: 2019 novel coronavirus (2019-nCoV) pneumonia

2019-nCoV epidemic: address mental health care to empower society

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

WHO's Coronavirus disease (COVID-19) advice for the public

The authors disclose no conflict of interest.

https://orcid.org/0000-0002-3318-4219